

Supplemental Figure 1. Radiolabeling of <sup>18</sup>F-BCPP-EF (A), <sup>18</sup>F-BCPP-BF (B), and <sup>18</sup>F-BMS (C). Syntheses of precursors and standard compounds of <sup>18</sup>F-BCPP-EF and <sup>18</sup>F-BCPP-BF were conducted according to a previous report (19).



Supplemental Figure 2. Inhibition of specific binding of <sup>3</sup>H-dihydrorotenone by BCPP-EF, BCPP-BF, and BMS in bovine cardiomyocyte submitochondrial particles (SMP). Specific binding of <sup>3</sup>H-dihydrorotenone at each point was plotted against concentrations of each test compound to determine the 50% inhibition (IC<sub>50</sub>) values, which were converted to the inhibition constant (Ki).



Supplemental Figure 3. Correlation analysis between the damaged areas determined by TTC staining and <sup>18</sup>F-BCPP-EF in the rat brains of PIT model. Brains were dissected at Day 1 for TTC staining after PET imaging with <sup>18</sup>F-BCPP-EF, and damaged areas detected by both methods were plotted.